Regeneus Ltd. (AU:CMB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cambium Bio Limited has received Fast Track designation from the FDA for Elate Ocular, a promising treatment for moderate to severe dry eye disease. This designation could expedite the drug’s development and review process, potentially bringing it to market sooner. The company’s Phase 3 trials are expected to begin in the second quarter of 2025.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.